Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Cao

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
Journal of the American College of Cardiology|November 19, 2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCIMarco Valgimigli, Davide Cao, Dominick J Angiolillo, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
International Journal of Cardiology|August 20, 2020
Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registryRidhima Goel, Samantha Sartori, Davide Cao, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 22, 2024
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromesDavide Cao, Pascal Vranckx, Marco Valgimigli, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 16, 2025
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programmeAngelo Oliva, Dominick J Angiolillo, Marco Valgimigli, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 7, 2023
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCIMarco Valgimigli, Alessandro Spirito, Samantha Sartori, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
Journal of the American College of Cardiology|November 19, 2021
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCIMarco Valgimigli, Davide Cao, Dominick J Angiolillo, et al.
European Heart Journal|August 23, 2021
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKDGiulio G Stefanini, Carlo Briguori, Davide Cao, et al.
International Journal of Cardiology|August 20, 2020
Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registryRidhima Goel, Samantha Sartori, Davide Cao, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 22, 2024
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromesDavide Cao, Pascal Vranckx, Marco Valgimigli, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 16, 2025
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programmeAngelo Oliva, Dominick J Angiolillo, Marco Valgimigli, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKDPayam Dehghani, Davide Cao, Usman Baber, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 18, 2022
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG studyGennaro Sardella, Frans J Beerkens, George Dangas, et al.
JACC. Cardiovascular Interventions|October 7, 2023
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCIMarco Valgimigli, Alessandro Spirito, Samantha Sartori, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Pageof 15